Company Profile For ViroPharma Incorporated

ViroPharma Incorporated (Viropharma), is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases. As of December 31, 2008, the Company had two marketed products and three development programs. It markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the United States and its territories. During the year ended December 31, 2008, three wholesalers represented 94% of the total net product sales. ViroPharma has three development programs in its product pipeline. ViroPharma is developing two new product candidates, maribavir for the prevention and treatment of cytomegalovirus (CMV) disease and non-toxigenic strains of Clostridium difficile infection (NTCD) for the treatment and prevention of Clostridium difficile infection (CDI). On October 21, 2008, the Company acquired Lev Pharmaceuticals, Inc. (Lev).

BRIEF: For the nine months ended 30 September 2009 ViroPharma Incorporated's revenues increased 22% to $222.6M. Net loss totaled $23.1M, vs. an income of $66.3M. Revenues reflect the presence of the cinryze product sales. Net loss reflects higher selling, general & administrative expenses, increased amortization of intangible assets and the presence of goodwill impairment expense and a fall in interest income.

ViroPharma Incorporated
397 Eagleview Boulevard
Exton   PA   19341
P: +1610.4587300
F: +1610.4587380

201